Fact-checked by Grok 2 weeks ago

Orthoflavivirus

Orthoflavivirus is a genus of enveloped, positive-sense single-stranded RNA viruses in the family Flaviviridae, characterized by a genome of approximately 9.2–11.0 kb that encodes a single long open reading frame flanked by 5' and 3' non-coding regions. These viruses exhibit spherical virions about 50 nm in diameter with icosahedral-like symmetry, featuring envelope proteins E and M on the surface. Primarily arthropod-borne, Orthoflavivirus species cycle between hematophagous arthropod vectors—such as mosquitoes (about 50% of species) and ticks (about 28%)—and vertebrate hosts, including mammals, birds, and reptiles, with some capable of direct transmission between vertebrates without vectors. Notable members include mosquito-borne pathogens like dengue virus (DENV), Zika virus (ZIKV), yellow fever virus (YFV), Japanese encephalitis virus (JEV), and West Nile virus (WNV), as well as tick-borne viruses such as tick-borne encephalitis virus (TBEV), many of which cause significant human diseases ranging from mild febrile illness to severe neurological disorders and hemorrhagic fever. Formerly classified as the genus Flavivirus, the taxon was renamed Orthoflavivirus in 2023 by the International Committee on Taxonomy of Viruses (ICTV) to distinguish it from newly established genera for insect-specific and no-known-vector flaviviruses, reflecting phylogenetic analyses that highlight distinct evolutionary branches within the . This renaming also involved adopting species , such as Orthoflavivirus denguei for the including DENV, to improve clarity in viral . Replication occurs in the , where the viral is translated into a polyprotein cleaved into structural (C, prM/M, E) and non-structural (NS1–NS5) proteins; the viruses enter host cells via and assemble at the before maturing in the Golgi apparatus. With 53 recognized , Orthoflavivirus pose major challenges globally, particularly in tropical and subtropical regions, due to their competence, human encroachment on habitats, and potential for via or recombination.

History and nomenclature

Early discoveries

The discovery of the yellow fever virus (YFV) marked a pivotal moment in understanding orthoflaviviruses, when in 1901, the U.S. Army Yellow Fever Commission, led by , demonstrated through human volunteer experiments that the disease was caused by a filterable agent transmitted by mosquitoes. This work built on earlier hypotheses by and confirmed mosquito-borne transmission, shifting focus from contaminated water to vectors as the primary mode of spread. Although actual laboratory isolation of YFV occurred later in 1927, Reed's findings established YFV as the prototype orthoflavivirus and highlighted the role of urban mosquito cycles in epidemics. Subsequent isolations expanded recognition of the genus. The (WNV) was first isolated in 1937 from the blood of a febrile woman in the West Nile district of , during surveys of undiagnosed fevers, using intracerebral inoculation in mice; it was later recognized as a mosquito-borne causing mild febrile illness in humans and . The (JEV) was first isolated in 1935 from the brain of a fatal human case in , during investigations into encephalitis outbreaks linked to rice farming seasons and Culex mosquitoes. This isolation, achieved via intracerebral inoculation in mice, confirmed JEV as a neurotropic orthoflavivirus distinct from poliomyelitis. Similarly, the (TBEV) was isolated in 1939 by Soviet scientists from patients and ticks in the Far Eastern during an outbreak investigation, establishing it as the prototype tick-borne orthoflavivirus transmitted by Ixodes ticks. (DENV) followed with its initial isolation in 1943 by from serum of U.S. soldiers in , using similar mouse inoculation techniques during outbreaks. These efforts identified DENV as another mosquito-transmitted agent, primarily by Aedes species, causing febrile illness rather than severe . Early serological studies in the 1930s and 1940s played a crucial role in linking these viruses to vectors. Complement-fixation and neutralization assays revealed among YFV, JEV, DENV, WNV, and TBEV, suggesting a shared antigenic group transmitted by hematophagous . Experimental transmissions, such as infecting monkeys with mosquito-fed blood or bites, further corroborated vector competence, distinguishing orthoflaviviruses from non--borne pathogens. Initial classification faced challenges due to limited morphological data, relying on serological profiles and clinical syndromes until the 1950s. Orthoflaviviruses were tentatively grouped as "Group B arboviruses" based on hemagglutination-inhibition tests showing antigenic relatedness among mosquito-borne agents like YFV, DENV, WNV, and JEV, as well as tick-borne ones like TBEV. The advent of in the mid-1950s resolved these ambiguities by visualizing the enveloped, spherical virions approximately 40-50 nm in diameter, confirming their distinct ultrastructure and separating them from non-enveloped enteroviruses.

Taxonomic evolution and name change

The genus Flavivirus was formally established in 1985 by the International Committee on Taxonomy of Viruses (ICTV) as part of the newly created family Flaviviridae, encompassing small enveloped viruses with positive-sense single-stranded RNA genomes primarily transmitted by arthropods and infecting vertebrates. This taxonomic placement separated these agents from related groups like togaviruses, based on shared morphological, biochemical, and serological properties, with the genus initially including viruses such as yellow fever virus and dengue virus as prototypes. In 2004, the Flaviviridae Study Group proposed refined species demarcation criteria for the genus Flavivirus, emphasizing genetic relatedness alongside ecological and antigenic factors; specifically, viruses sharing more than 84% amino acid identity in the envelope (E) protein were considered members of the same , while those below this threshold, combined with differences in vector or host associations, warranted separate . These criteria facilitated the organization of over 50 recognized by integrating phylogenetic data from complete sequences, addressing ambiguities in earlier serological-based groupings. To resolve ongoing nomenclatural ambiguity—where terms like "flavivirus" could refer interchangeably to the genus, family, or vernacular usage—the ICTV approved the renaming of the genus Flavivirus to Orthoflavivirus in April 2023, following a 2022 proposal by the Flaviviridae Study Group. The prefix "ortho-" denotes "true" flaviviruses sensu stricto, distinguishing the arthropod-borne members from other Flaviviridae genera like Hepacivirus (e.g., hepatitis C virus); concurrently, the ICTV extended binomial nomenclature to all species across the family, adopting formats such as Orthoflavivirus dengue for dengue virus species. Recent updates in 2024 and 2025 have incorporated protein structure predictions alongside sequence data to reclassify unassigned flaviviruses, enabling the integration of structural phylogenies for glycoprotein and polymerase domains to refine genus boundaries and assign novel isolates. For instance, analyses of envelope glycoprotein structures across Flaviviridae have revealed evolutionary divergences that support the reallocation of certain insect-specific viruses previously unclassified within Orthoflavivirus. These advancements, ratified in the ICTV's 2024 taxonomy release, enhance demarcation by quantifying structural similarities, such as root-mean-square deviation in predicted folds, to complement amino acid identity thresholds.

Virology

Virion structure

The orthoflavivirus virion is a spherical particle about 50 nm in , enveloped by a host-derived that confers stability and facilitates entry into host cells. The envelope surrounds a nucleocapsid , exhibiting pseudo-T=3 icosahedral symmetry without true spikes at neutral pH, which distinguishes it from other enveloped viruses. The virion incorporates three structural proteins encoded by the viral genome: the protein C (11 ), which forms a protein-RNA complex inside the ; the precursor prM (26 ), which is cleaved to mature M (8 ) during virion release; and the E (50 ), the primary surface protein responsible for receptor binding and . These proteins assemble such that 180 copies of E form 90 dimers arranged in a characteristic on the surface, with M proteins intercalated beneath, while multiple C proteins associate with the genomic to create the internal core. Cryo-electron microscopy (cryo-EM) studies have provided high-resolution models of orthoflavivirus virions, revealing the E protein dimers tiling the outer surface in an icosahedral-like and the condensed RNA genome packaged within the C protein shell. For instance, reconstructions of mature at 3.5 Å resolution demonstrate how E dimers lie flat against the lipid envelope, enabling efficient particle formation without protruding domains. These structures highlight the virion's compact architecture, with the nucleocapsid core occupying the central volume and interacting minimally with the envelope in mature particles. Glycosylation of the E protein, typically at one or two N-linked sites depending on the virus species, plays a critical role in host cell attachment by modulating interactions with cellular receptors and influencing viral . This enhances E protein stability and facilitates binding to attachment factors such as or glycosaminoglycans on target cells, thereby promoting efficient entry.

Genome organization

The genome of orthoflaviviruses consists of a positive-sense, single-stranded molecule approximately 11 kb in length, ranging from 9.2 to 11.0 kb across species. It is capped at the 5' end with a type 1 cap structure (m⁷GpppAmpG) that facilitates by host machinery, and lacks a 3' poly(A) tail, instead featuring a conserved dinucleotide sequence (CU) at the terminus, often preceded by a polyuridine (poly-U) tract within the 3' (UTR). The genome is flanked by 5' and 3' UTRs of variable lengths (typically 95–150 at the 5' end and 400–700 at the 3' end), which contain conserved RNA sequence motifs critical for replication and packaging, though these regions exhibit species-specific variations. The viral RNA harbors a single long open reading frame (ORF) exceeding 10,000 nucleotides, which encodes a polyprotein of about 3,400 . This polyprotein undergoes co- and post-translational processing by viral (NS2B-NS3 ) and host proteases to yield 10 mature proteins: three structural components—the protein (C, ~11 kDa), precursor membrane protein (prM, ~26 kDa, which is cleaved to mature M, ~8 kDa), and envelope glycoprotein (E, ~50 kDa)—and seven non-structural proteins (NS1, ~46 kDa; NS2A, ~22 kDa; NS2B, ~14 kDa; NS3, ~70 kDa; NS4A, ~16 kDa; NS4B, ~27 kDa; and NS5, ~103 kDa). The structural proteins form the virion core and envelope, while the non-structural proteins support RNA replication, modulation of host responses, and virion assembly. A hallmark of orthoflavivirus genome organization is the presence of conserved functional motifs within the encoded proteins, notably the GDD in the C-terminal RNA-dependent RNA polymerase (RdRp) domain of NS5, which forms the catalytic for de novo RNA synthesis. Genomes within the same orthoflavivirus typically share 70–90% identity, underscoring their genetic stability and evolutionary cohesion, with higher identity (>90%) often observed among strains of a single like dengue virus serotype 1. This level of conservation facilitates antigenic and informs taxonomic demarcation, where interspecies differences exceed these thresholds.

Replication and life cycle

Orthoflaviviruses initiate infection through attachment of the envelope (E) glycoprotein to host cell surface receptors, such as DC-SIGN (CD209) on dendritic cells and mannose receptors on macrophages, facilitating receptor-mediated endocytosis. In the acidic environment of endosomes, conformational changes in the E protein dimers trigger fusion between the viral envelope and endosomal membrane, releasing the positive-sense single-stranded RNA genome into the cytoplasm. This entry mechanism is conserved across orthoflaviviruses, including dengue and Zika viruses, and exploits host glycosaminoglycans and lectins for enhanced binding efficiency. Upon uncoating, the viral RNA genome serves directly as mRNA for translation on (ER)-associated ribosomes, producing a single polyprotein precursor that encompasses structural (C, prM/M, E) and non-structural (NS1–NS5) proteins. of this polyprotein occurs co- and post-translationally by host signal peptidase for structural proteins and the viral NS2B-NS3 complex for non-structural regions, enabling functional maturation of viral components. The structural proteins, briefly referenced from virion composition, interact with the nascent polyprotein to initiate downstream processes. RNA replication takes place within specialized cytoplasmic vesicles derived from ER membranes, induced by viral non-structural proteins including NS4A and NS4B, forming a replication that shields double-stranded RNA intermediates from innate immune detection. The NS5 protein, acting as the (RdRp), synthesizes negative-sense RNA intermediates using the positive-sense as template, followed by production of new positive-sense genomic RNAs for packaging and further translation cycles. Host factors like pathways, including glycerophospholipid remodeling, support vesicle formation and polymerase activity, ensuring efficient amplification of the . Assembly of progeny virions occurs at the , where the (C) protein packages positive-sense into immature nucleocapsids that bud into the ER lumen, acquiring a with prM and E proteins. During transport through the secretory pathway to the Golgi apparatus, host cleaves prM to mature M protein, inducing E protein rearrangement into the infectious, spiky conformation essential for subsequent cell entry. Fully mature virions are then released via , completing the replication cycle while evading lysosomal degradation through pH-dependent maturation.

Molecular mechanisms

RNA secondary structure elements

The 5' untranslated region (UTR) of orthoflaviviruses spans approximately 100 and adopts a conserved Y-shaped secondary structure formed by two principal stem-loop elements: stem-loop A () and stem-loop B (SLB). , located at the 5' terminus, consists of a stable basal with an apical loop that serves as a promoter for recruitment, while SLB features a shorter and contributes to the overall branched architecture. This Y-shaped motif enables long-range base-pairing interactions between complementary sequences in the 5' and 3' UTRs, promoting genome cyclization necessary for efficient replication initiation. Furthermore, the structured 5' supports an (IRES)-like mechanism, facilitating cap-independent translation by recruiting host ribosomes directly to the without reliance on the 5' cap structure. In contrast, the 3' UTR is longer, ranging from 400 to 700 across orthoflavivirus species, and folds into a complex array of motifs that enhance viral stability and synthesis. Key elements include two tandem structures (DB1 and DB2), each comprising paired stems connected by loops, which together form a compact, H-shaped domain critical for replication enhancer activity by interacting with viral and host proteins. These dumbbells are further stabilized by adjacent structures, where distal loops base-pair with stems to create tertiary folds that resist degradation and promote processivity. Upstream of the terminal poly-U/UA tract, a conserved (cHP) forms a stable stem-loop that anchors long-range interactions, bridging the 3' to upstream regions and maintaining overall UTR integrity during the viral . Experimental characterization of these RNA secondary structures has relied on techniques such as selective 2'-hydroxyl acylation analyzed by (SHAPE) probing, which reveals nucleotide-level reactivity to map flexible loops and rigid stems, confirming the predicted Y-shape in the 5' UTR and pseudoknotted dumbbells in the 3' UTR for viruses like dengue and Zika. Complementary studies have disrupted specific base pairs—for instance, altering the SLA apical loop or cHP stem—resulting in severe defects in cyclization, , and replication efficiency, thereby validating the functional importance of these motifs without altering primary sequence conservation.

sfRNA production and roles

Subgenomic flaviviral (sfRNA) is produced during orthoflavivirus through the incomplete of the viral genomic by the host 5'-3' exoribonuclease XRN1. This process begins when XRN1, which typically degrades uncapped mRNAs in a 5'-to-3' direction, encounters structured elements within the 3' (UTR) of the genomic . Specifically, XRN1 stalls at resistant RNA motifs, such as the (DB) structures and the conserved (cHP), preventing complete exonucleolytic processing and yielding noncoding sfRNA fragments of approximately 300-500 in length. These structures form compact folds, including ring-like helices and pseudoknots, that physically impede XRN1's activity, ensuring sfRNA accumulation in infected cells. sfRNAs exert multiple roles in modulating host responses to favor and . A key function is the inhibition of type I (IFN) signaling, achieved by sfRNA binding directly to the domain of TRIM25, an E3 essential for activating the viral RNA sensor RIG-I. This interaction disrupts TRIM25-mediated ubiquitination of RIG-I's CARD domains, thereby blocking downstream IFN-β and attenuating innate antiviral immunity. In orthoflaviviruses like , this mechanism enhances viral fitness by evading early immune detection. Beyond immune evasion, sfRNA suppresses cytopathicity in mammalian cells, promoting persistent without inducing rapid . By inhibiting global XRN1 activity through prolonged association, sfRNA stabilizes host mRNAs and reduces apoptotic pathways, such as those involving caspase-3 and PI3K-AKT signaling, allowing sustained viral propagation. In mosquito vectors, sfRNA further enhances replication by binding to host DEAD-box helicases like DDX6 homologs, which facilitates viral transmission; for instance, in , sfRNA interaction with these factors boosts infectivity in salivary glands. sfRNA production and functions vary across orthoflavivirus species, reflecting adaptations to diverse hosts. , for example, generates multiple sfRNA species—up to three or four per —due to duplicated xrRNA elements and structures in its 3' UTR, with the largest isoform often predominant and contributing to serotype-specific immune antagonism and vector competence. In contrast, tick-borne species like typically produce a single sfRNA, underscoring evolutionary divergences in and host interactions.

Evolution

Origins and diversification

Sequence-based analyses estimate the divergence of vertebrate-infecting Orthoflavivirus lineages from ancestral insect-specific flaviviruses at approximately 85,000–120,000 years ago. However, endogenous viral elements integrated in host genomes indicate the broader family originated over 100 million years ago, suggesting deeper evolutionary roots for the group. This origin aligns with the emergence of dual-host cycles involving vectors and vertebrates, evolving from viruses restricted to hosts that lacked the ability to replicate in mammalian cells. Phylogenetic studies show variable evidence for co-divergence with hosts in some lineages. Diversification within the genus has primarily been driven by high mutation rates characteristic of viruses, varying by from approximately 10^{-5} to 10^{-4} substitutions per per year, facilitated by the error-prone nature of the viral lacking proofreading activity. This polymerase infidelity contributes to antigenic drift, allowing gradual accumulation of in surface glycoproteins that enable immune evasion and to new hosts without major structural changes. Recombination events, while possible in co-infected cells, are rare in orthoflaviviruses due to their single-stranded genome and segmented-like replication strategy, occurring at frequencies low enough to have minimal impact on overall phylogeny compared to point . Fossil evidence of preserved in , dating back approximately 100 million years, indicates the ancient presence of potential vectors capable of supporting cycles, predating the recent diversification of vertebrate-infecting orthoflaviviruses. Such records suggest that the ecological split between and vectors occurred long before the adaptation of orthoflaviviruses to distinct modes.

Phylogenetic analysis

Phylogenetic analyses of orthoflaviviruses have established the as comprising four principal s delineated by specificity and ecology: the tick-borne clade, the mosquito-borne clade (subdivided into virus and supergroups), the no-known-vector clade, and the insect-specific clade. These groupings are inferred primarily from sequences of the highly conserved non-structural protein 5 (NS5) gene, which encodes the and exhibits sufficient variability to resolve deep evolutionary relationships while maintaining alignability across diverse taxa. Maximum-likelihood and Bayesian phylogenetic trees based on NS5 or sequences consistently recover these clades with strong statistical support, often exceeding 95% bootstrap values or 0.99 posterior probabilities for major nodes. For instance, the divergence between the tick-borne and mosquito-borne clades is marked by substantial , with pairwise identities averaging approximately 56% in the NS5 region, reflecting an early split in the genus's history. The (E) protein , while less conserved, complements NS5-based phylogenies by informing serological and antigenic , as it drives immune and is thus prioritized for studies of serocomplexes within clades. Recent cryo-EM structures of NS5 in complex with stem-loop A (SLA) RNA from representative mosquito-borne orthoflaviviruses, such as , reveal conserved interaction motifs essential for replication.

Taxonomy and classification

Species criteria and list

The International Committee on Taxonomy of Viruses (ICTV) defines species demarcation within the genus Orthoflavivirus using a multifaceted set of criteria, including and deduced data, antigenic characteristics, geographic association, vector association, host association, disease association, and ecological characteristics. These criteria integrate genetic divergence with biological and epidemiological factors to distinguish , particularly for closely related viruses that may share phylogenetic proximity. In practice, viruses are often considered distinct if they share less than approximately 84% identity across the complete genome, alongside other criteria such as antigenic and ecological differences, with identity in the E protein also informing distinctions. As of 2025, the ICTV recognizes 53 species in the genus Orthoflavivirus, reflecting ongoing genomic surveillance and taxonomic updates. All species possess a positive-sense, single-stranded RNA genome of approximately 10,700–11,300 nucleotides, encoding a single polyprotein that is cleaved into structural and non-structural proteins. Host ranges generally involve vertebrate amplification (such as mammals or birds) and arthropod transmission, though some species are restricted to insects or lack known vertebrate hosts. Notably, the four antigenically distinct serotypes of dengue virus (DENV-1 through DENV-4) are unified as the single species Orthoflavivirus denguei due to their overlapping geographic distributions, shared vectors, and similar disease profiles in humans, despite nucleotide identities of 65–75% between serotypes. The following table summarizes the recognized species, with approximate genome sizes (typically ~11 kb) and brief host range overviews based on established associations.
Species NameGenome Size (nt)Host Range Summary
Orthoflavivirus gadgetsense~10,800Birds, ticks; occasional mammals
Orthoflavivirus kyasanurense~10,800Monkeys, humans, ticks
Orthoflavivirus langatense~10,800Rodents, ticks; mild human infections
Orthoflavivirus loupingi~10,800Sheep, humans, ticks
Orthoflavivirus omskense~10,800Rodents, humans, ticks
Orthoflavivirus powassanense~10,800Small mammals, humans, ticks
Orthoflavivirus royalense~10,800Seabirds, ticks
Orthoflavivirus encephalitidis~10,900Mammals, birds, humans, ticks
Orthoflavivirus meabanense~10,800Seabirds, ticks
Orthoflavivirus saumarezense~10,800Seabirds, ticks
Orthoflavivirus tyuleniyense~10,800Seabirds, ticks
Orthoflavivirus kadamense~10,800Ruminants, ticks
Orthoflavivirus aroaense~10,800Birds, mosquitoes
Orthoflavivirus denguei~10,700–10,800Humans, primates, mosquitoes
Orthoflavivirus cacipacoreense~10,900Rodents, mosquitoes
Orthoflavivirus japonicum~11,000Birds, mosquitoes
Orthoflavivirus koutangoense~10,800Rodents, ticks
Orthoflavivirus murrayense~10,900Marsupials, mosquitoes
Orthoflavivirus louisense~10,800Birds, mosquitoes
Orthoflavivirus usutuense~11,000Birds, humans, mosquitoes
Orthoflavivirus nilense~10,800Birds, mosquitoes
Orthoflavivirus yaoundeense~10,900Primates, mosquitoes
Orthoflavivirus kokoberaorum~10,900Marsupials, mosquitoes
Orthoflavivirus bagazaense~10,800Birds, humans, mosquitoes
Orthoflavivirus ilheusense~10,900Primates, birds, mosquitoes
Orthoflavivirus israelense~10,900Birds, humans, mosquitoes
Orthoflavivirus ntayaense~10,900Birds, mosquitoes
Orthoflavivirus tembusu~10,900Ducks, mosquitoes
Orthoflavivirus zikaense~10,800Primates, humans, mosquitoes
Orthoflavivirus sepikense~10,800Humans, mosquitoes
Orthoflavivirus wesselsbronense~10,900Ruminants, humans, mosquitoes
Orthoflavivirus flavi~10,800Birds, mosquitoes
Orthoflavivirus kedougouense~10,800Primates, mosquitoes
Orthoflavivirus banziense~10,900Rodents, humans, mosquitoes
Orthoflavivirus boubouiense~10,800Rodents, mosquitoes
Orthoflavivirus edgehillense~10,900Marsupials, mosquitoes
Orthoflavivirus jugraense~10,800Unknown vertebrates, mosquitoes
Orthoflavivirus saboyaense~10,900Bats, mosquitoes
Orthoflavivirus ugandaense~10,900Birds, mosquitoes
Orthoflavivirus entebbeense~10,800Bats, mosquitoes
Orthoflavivirus yokoseense~10,800Bats, mosquitoes
Orthoflavivirus apoiense~10,700Insects only (no known vertebrate host)
Orthoflavivirus cowboneense~10,700Insects only (no known vertebrate host)
Orthoflavivirus jutiapaense~10,700Insects only (no known vertebrate host)
Orthoflavivirus modocense~10,800Rodents (no known arthropod vector)
Orthoflavivirus viejaense~10,800Rodents (no known arthropod vector)
Orthoflavivirus perlitaense~10,700Insects only (no known vertebrate host)
Orthoflavivirus bukalasaense~10,700Insects only (no known vertebrate host)
Orthoflavivirus careyense~10,700Insects only (no known vertebrate host)
Orthoflavivirus dakarense~10,800Rodents (no known arthropod vector)
Orthoflavivirus montanaense~10,800Rodents (no known arthropod vector)
Orthoflavivirus phnompenhense~10,700Insects only (no known vertebrate host)
Orthoflavivirus bravoense~10,700Insects only (no known vertebrate host)
This list encompasses the full ICTV-recognized species, with insect-specific examples (e.g., Orthoflavivirus apoiense) highlighting those without known vertebrate hosts, often identified through mosquito surveillance sequencing. Recent genomic efforts from 2024–2025 have sequenced additional insect-specific variants, such as Aedes-associated flaviviruses, potentially supporting future species proposals under ICTV criteria, though none have been formally ratified yet.

Grouping by transmission vectors

Orthoflaviviruses are ecologically diverse and are primarily grouped by their transmission vectors, which determine their host ranges, geographic distribution, and public health implications. This vector-based classification highlights patterns of arthropod-mediated transmission to vertebrates, direct vertebrate-to-vertebrate spread, or restriction to invertebrate hosts alone. Approximately 12 species are tick-borne, transmitted mainly by Ixodes ticks through feeding on infected vertebrate hosts like mammals and birds, enabling maintenance via transstadial and transovarial routes in the vector. Over 30 species fall into the mosquito-borne group, vectored predominantly by and mosquitoes in enzootic cycles involving , , or other mammals before spilling over to humans. These viruses often co-circulate in shared vectors, as seen with and both transmitted by in tropical urban environments, facilitating sequential or simultaneous outbreaks. Five species lack known arthropod vectors and are sustained through non-viremic transmission among vertebrate reservoirs such as rodents or bats, reflecting adaptation to direct host-to-host contact without intermediate vectors. Insect-specific orthoflaviviruses, which do not infect vertebrates, form a distinct group confined to insect hosts like mosquitoes, often persisting via vertical transmission and potentially influencing the vector competence for dual-host viruses. As of 2025, emerging vectors such as invasive ticks are expanding their ranges into new regions, driven by habitat changes, which heightens risks for tick-borne species like in previously unaffected areas of . exacerbates these patterns by enhancing vector competence through warmer temperatures that accelerate replication in arthropods and extend active vector seasons for both ticks and mosquitoes.

Tick-borne species

The tick-borne species of the genus Orthoflavivirus are arthropod-borne viruses primarily transmitted by ixodid ticks, with a global distribution but localized endemic foci shaped by vector ecology. These viruses are classified into two main groups: the mammalian tick-borne virus group, which affects mammals including humans and , and the seabird tick-borne virus group, which circulates in hosts. Unlike mosquito-borne orthoflaviviruses, tick-borne species are more prevalent in temperate and boreal regions, where they cause neurological and hemorrhagic diseases through tick bites during warmer months. The mammalian tick-borne group includes several notable species, with Tick-borne encephalitis virus (Orthoflavivirus encephalitidis, TBEV) being the most significant, endemic to forested areas across and northern from to the and . TBEV infection leads to , a biphasic illness progressing to severe , , or in 20-30% of symptomatic cases, with a case-fatality rate of 0.5-20% depending on subtype. Another key member is Powassan virus (Orthoflavivirus powassanense, POWV), restricted to , particularly the , , and eastern , where it causes neuroinvasive disease including and long-term neurological sequelae in up to 50% of survivors. Other species in this group, such as Kyasanur Forest disease virus (Orthoflavivirus kyasanurense, KFDV) in southwestern and Omsk hemorrhagic fever virus (Orthoflavivirus omskense, OHFV) in western , , are associated with hemorrhagic fevers featuring high fever, bleeding, and mortality rates of 3-10% and 1-3%, respectively. The seabird tick-borne group consists of viruses adapted to marine and coastal environments, exemplified by Tyuleniy virus (Orthoflavivirus tyuleniyense, TYUV), which is isolated from seabirds and their ectoparasitic ticks () in the northern , , and regions including Tyuleniy Island, . TYUV and related species like Meaban virus and Saumarez Reef virus do not cause significant disease in humans, focusing instead on avian reservoirs with no documented human pathogenicity. Recent surveillance has highlighted TYUV's genetic stability and low zoonotic potential, though it shares antigenic similarities with mammalian group viruses. In 2024, reports documented the expansion of TBEV's geographic range, driven by the northward and altitudinal migration of principal vectors and Ixodes persulcatus due to warming, with new endemic foci emerging in southern , northern , and parts of the . This shift has increased incidence rates by 20-50% in some European areas over the past decade. Serological assays reveal cross-reactivity within tick-borne Orthoflavivirus species, mediated by conserved epitopes on the envelope protein, which can lead to diagnostic challenges in co-endemic regions through false positives in and hemagglutination-inhibition tests.

Mosquito-borne species

Mosquito-borne orthoflaviviruses primarily circulate in tropical and subtropical regions, transmitted by species such as Aedes and Culex mosquitoes, with Aedes aegypti and Aedes albopictus favoring urban environments for dengue and Zika viruses, while Culex species like Culex tritaeniorhynchus and Culex pipiens serve as key vectors for Japanese encephalitis and West Nile viruses. These viruses pose significant public health threats due to their potential for large-scale epidemics and severe neurological or hemorrhagic manifestations in humans. The Japanese encephalitis antigenic group includes prominent human pathogens such as virus (JEV), which is endemic across and causes an estimated 100,000 clinical cases annually (as of 2024), primarily manifesting as acute with high mortality or long-term neurological sequelae. JEV transmission involves pigs as amplifying hosts and Culex mosquitoes, with widespread vaccination programs in endemic countries like , , and having substantially reduced incidence rates. (WNV), another member of this group, has a global distribution spanning , , the , , and , where it cycles between birds as reservoir hosts and Culex mosquitoes, occasionally spilling over to humans and equines to cause neuroinvasive disease in up to 1% of infections. WNV emerged in the in 1999, leading to thousands of neuroinvasive cases in the United States alone during peak years, highlighting its potential for rapid geographic expansion. The dengue antigenic group encompasses (DENV) serotypes 1–4, which are the leading cause of arthropod-borne viral illness worldwide, infecting an estimated 400 million people annually in tropical and subtropical regions and occasionally progressing to severe dengue hemorrhagic fever or dengue shock syndrome. Transmitted mainly by in urban settings, DENV's hyperendemic circulation results from co-circulation of multiple serotypes, increasing risks of secondary infections and . In , the experienced an unprecedented surge with over 13 million reported cases—more than triple the previous year's total—driven by climatic factors and , underscoring the virus's escalating global burden. (ZIKV), also in this group, gained prominence during the 2015–2016 across the , where it infected over 1.5 million people in alone and was causally linked to congenital Zika syndrome, including in newborns. Primarily vectored by species, ZIKV continues to co-circulate with DENV in regions like , where genomic analyses in confirmed ongoing transmission of South American-origin strains amid febrile illness outbreaks.

Species without known vectors

Orthoflaviviruses without known vectors, also referred to as no-known-vector (NKV) orthoflaviviruses, are maintained in vertebrate-only transmission cycles, primarily among and bats, without reliance on intermediaries. These viruses represent a distinct within the genus, diverging from arthropod-borne species through evolutionary adaptations that favor direct host-to-host spread. A prominent example is Modoc virus (MODV), first isolated in 1958 from deer mice (Peromyscus maniculatus) in , though it has since been detected across the and . In its natural hosts, MODV typically causes or mild infections and is non-pathogenic, with transmission occurring horizontally through direct contact, including exposure to saliva during grooming or aggressive interactions. Human spillover is rare, with only a few documented cases of linked to MODV exposure, often in laboratory settings or through contact. Another key example is Rio Bravo virus (RBV), isolated in 1954 from big brown bats (Eptesicus fuscus) in and subsequently found in bats across the , including and Trinidad. RBV circulates asymptomatically in bat reservoirs, with transmission likely via or in roosts, facilitating close-contact spread among colonial species like Mexican free-tailed bats (Tadarida brasiliensis). Rare human infections have been reported, manifesting as mild febrile illness, but without significant morbidity. Genomic analyses of NKV orthoflaviviruses, such as MODV (10,600 ) and RBV (10,742 ), reveal features indicative of lost vector adaptation, including the absence of mosquito-specific motifs in the 3' untranslated region (UTR), such as the CS1 element, which is conserved in arthropod-borne counterparts. This structural divergence supports their restriction to vertebrate cycles, with single-stranded positive-sense genomes encoding a polyprotein that processes into structural and nonstructural proteins typical of the genus. Recent surveillance efforts have expanded understanding of bat-associated NKV orthoflaviviruses, identifying as a for flavivirus diversity in bats, with elevated epidemic potential in families like Rhinolophidae and . A 2025 phylogeographic study across global bat populations underscored this regional concentration, highlighting anthropogenic pressures that may increase spillover risks from bats in Southeast Asian s.

Insect-specific and newly sequenced species

Insect-specific orthoflaviviruses (ISOVs), also known as insect-specific flaviviruses, represent a subset of the that replicate exclusively in hosts such as mosquitoes, without establishing in s. These viruses are maintained through in populations, often via transovarial routes in female mosquitoes, and exhibit no known pathogenicity to mammals or . Unlike dual-host orthoflaviviruses, ISOVs demonstrate strict host , failing to produce infectious particles in vertebrate cell lines due to barriers in entry, replication, and maturation. The cell fusing agent virus (CFAV) serves as the prototypical ISOV, first isolated in 1975 from an Aedes aegypti cell line and subsequently detected in wild mosquitoes worldwide. CFAV induces formation in insect cells but cannot replicate in cells, even when inoculated at high multiplicities, confirming its inability to infect mammalian hosts. rates in naturally infected Aedes exceed 90%, enabling persistent circulation without vertebrate involvement. Kamiti River virus (KRV), another well-characterized ISOV, was isolated in 2003 from Aedes mcintoshi mosquitoes collected near the Kamiti River in . Like CFAV, KRV is transmitted vertically in mosquito populations and replicates efficiently in Aedes-derived cell lines but not in cells, with genomic features including a uniquely long 3' that generates high levels of small interfering RNAs during infection. KRV has been detected in diverse mosquito species across and , highlighting its ecological persistence. Advancements in metagenomic sequencing have expanded the catalog of ISOVs and unclassified orthoflaviviruses, particularly from mosquito pools in understudied regions. Between 2024 and 2025, several novel sequences were reported, including unclassified flaviviruses from Aedes and Culex mosquitoes in sub-Saharan Africa, such as variants related to Kédougou virus isolated in Senegal and the Central African Republic. These discoveries, often from environmental surveillance, reveal diverse lineages with no prior vertebrate associations. Approximately 12 such newly sequenced orthoflaviviruses exhibit serological evidence of human exposure in endemic areas, though replication incompetence in vertebrates limits immediate zoonotic risk. A key genetic distinction in ISOVs is the absence or suboptimal configuration of the cleavage site in the precursor membrane (prM) protein, typically featuring an RXKR essential for prM processing into mature membrane () protein during virion assembly in s. In ISOVs like CFAV and KRV, this site lacks critical basic residues (e.g., at the P1 position), resulting in inefficient and production of immature, non-infectious particles in mammalian cells. This post-translational restriction, alongside entry barriers, enforces host specificity and prevents adaptation to vertebrate replication. The ecological role of ISOVs extends to mitigating orthoflavivirus , as persistent ISOV infections in mosquitoes induce exclusion (SIE), a phenomenon where prior ISOV occupancy blocks subsequent replication of vertebrate-infecting orthoflaviviruses like dengue or Zika in the vector's or salivary glands. Experimental co-infections demonstrate up to 90% reduction in of pathogenic strains, suggesting ISOVs as natural barriers to spillover and potential tools for strategies. This interference likely stems from competition for host factors or pathways, underscoring ISOVs' value in preventing zoonotic emergence.

Prevention and control

Vaccine development

Vaccine development for orthoflaviviruses has focused primarily on major pathogens transmitted by mosquitoes and ticks, with several licensed products available for (YFV), (JEV), (DENV), and (TBEV). The YF-VAX is a live-attenuated derived from the 17D strain, providing lifelong immunity in over 99% of recipients after a single dose. For JEV, the IXIARO (previously referred to as JE-VAX in earlier s) induces rates exceeding 95% with a two-dose regimen, offering protection against severe neurological disease. The chimeric tetravalent Dengvaxia (CYD-TDV) uses a YFV-17D backbone expressing DENV envelope proteins from all four serotypes, approved for use in endemic areas for individuals aged 9-45 with prior dengue exposure. Another licensed tetravalent DENV vaccine, Qdenga (TAK-003), is a live-attenuated using a DENV-2 backbone with chimeric genes from other serotypes; it is approved in over 40 countries as of 2025 for individuals aged 4-60 regardless of prior exposure, demonstrating 80% efficacy against symptomatic dengue and 90% against hospitalization in phase 3 trials, with sustained protection through 7 years. Additionally, s like TICOVAC for TBEV are licensed and demonstrate 95-99% efficacy against clinical disease following three doses. Emerging vaccine platforms in 2025 emphasize nucleic acid-based approaches, particularly mRNA technologies, to address viruses like (ZIKV) and (WNV) that lack approved vaccines. Moderna's mRNA-1893, an lipid nanoparticle-encapsulated vaccine encoding the ZIKV prM-E proteins, has shown safety and durable neutralizing antibody responses in phase 2 trials, eliciting sterilizing immunity in preclinical models without cross-reactive enhancement risks. For WNV, experimental mRNA candidates targeting the envelope protein are in early development, demonstrating robust humoral and cellular responses in animal studies. Efforts toward universal flavivirus vaccines target conserved epitopes, such as those in the envelope protein stem domain or non-structural proteins NS3 and NS5, to induce cross-protective T-cell responses across serotypes and species. Key challenges in orthoflavivirus vaccine development include (ADE), particularly for DENV, where sub-neutralizing antibodies from prior exposure or vaccination can exacerbate infection with heterologous serotypes, and the necessity for tetravalent formulations to ensure balanced immunity against all DENV serotypes without immunodominance. Dengvaxia exemplifies these issues, with overall of 60% against symptomatic dengue and up to 90% against severe in seropositive individuals, but it increases hospitalization by 1.5- to 2-fold in dengue-naïve (seronegative) vaccinees due to ADE, prompting WHO recommendations for pre-vaccination screening. These hurdles underscore the need for next-generation vaccines that prioritize T-cell-mediated protection and avoid ADE-prone epitopes to achieve broad, safe coverage.

Antiviral strategies and challenges

Nucleoside analogs represent a primary class of direct-acting antivirals targeting the non-structural protein 5 (NS5) (RdRp) of orthoflaviviruses, inhibiting viral genome replication by competing with natural . For instance, 7-deaza-2'-C-methyl (7DMA), a modified analog, demonstrates potent inhibition of RdRp activity across multiple orthoflaviviruses, including (WNV), (ZIKV), and virus (YFV), with EC50 values in the low nanomolar range in models. Similarly, , an approved inhibitor, exhibits broad-spectrum activity against YFV and (DENV) by mimicking and causing chain termination during synthesis. These compounds offer therapeutic potential but require further clinical evaluation for orthoflavivirus-specific indications. Monoclonal antibodies (mAbs) directed against the () provide another antiviral strategy by neutralizing viral entry into host cells through steric hindrance of receptor binding or processes. Broadly cross-reactive human mAbs, such as those targeting conserved epitopes on domain II or III of the E protein, have shown efficacy in preclinical models against DENV, ZIKV, and WNV, reducing and disease severity in animal challenge studies. For example, affinity-matured mAbs like mAb 2A10G6 neutralize multiple orthoflaviviruses by binding quaternary epitopes on the mature virion surface, preventing conformational changes necessary for infection. These biologics are particularly promising for , though challenges in cross-protection persist. Vector control remains a cornerstone of orthoflavivirus management, with the release of Wolbachia-infected mosquitoes significantly reducing DENV transmission by impairing viral replication within the . Field trials in endemic areas, such as , , reported up to 77% reduction in dengue incidence two years post-deployment, attributed to cytoplasmic incompatibility and reduced vector competence. However, widespread resistance in key vectors like and compromises traditional pyrethroid-based interventions, with resistance frequencies exceeding 90% in many Asian and African populations due to target-site mutations and metabolic detoxification. Orthoflaviviruses' high mutation rates, driven by error-prone RdRp lacking proofreading activity (approximately 10^{-4} to 10^{-5} mutations per per replication cycle), facilitate rapid of drug-resistant variants, as observed in escape mutants from nucleoside inhibitors in . This quasispecies diversity exacerbates antiviral evasion and complicates broad-spectrum therapy development. Additionally, global surveillance gaps hinder timely detection of emerging strains; for instance, underreporting in and has delayed identification of novel variants like lineages, with genomic sequencing coverage below 20% in many low-resource settings. Recent advances as of 2025 include glycoprotein-focused immunotherapies leveraging engineered mAbs against E protein epitopes to enhance potency and breadth, showing improved neutralization of DENV serotypes in nonhuman primate models without risks. Concurrently, CRISPR-based editing of mosquito vectors, such as targeting immunity-related s in , has demonstrated potential to reduce orthoflavivirus in laboratory strains, with field-applicable drives achieving over 90% in proof-of-concept studies. These innovations address hurdles but require ethical and ecological safeguards for deployment.